Dr David Gibson
Lecturer in Stratified Medicine
- School of Biomedical Sciences
- Research Institute
- Biomedical Sciences Research Institute
School of Biomedical Sciences
C-TRIC Building, Altnagelvin Area Hospital
Glenshane Road, Derry~Londonderry
- +44 28 7167 5663
After his Biochemistry degree, Dr David Gibson worked at Randox Laboratories Ltd, where he was responsible for designing and commercialising novel biochip array diagnostic tests.
He was awarded a PhD in 2001 from the Centre for Cancer Research and Cell Biology, Queen’s University Belfast (QUB), for research which exposed the role of cysteine proteinases in brain tumour invasion.
During a Wellcome Trust Fellowship Dr Gibson investigated the role of inflammation in a hypoxia driven model of diabetic retinopathy at the Centre of Vision and Vascular Science, QUB.
Since 2003 Dr Gibson focused his research efforts on the discovery and validation of protein biomarkers which could improve the management of arthritis patients.
During his time at the Rooney laboratory in the Centre of Infection and Immunity, QUB he spearheaded the use of proteomic and bioinformatics strategies to discover clinically useful biomarker candidates. He also identified post translational modifications in the Vitamin D binding protein that may act as a modulator of inflammation in juvenile arthritis patients.
In 2009, Dr Gibson was awarded a prestigious travel fellowship from Arthritis Research UK to conduct mass spectrometry based research at the Duncan laboratory at the University of Colorado, Denver over two years.
In 2013 Dr Gibson took up his post as Lecturer in Stratified Medicine and his research is focused on adult rheumatoid arthritis (RA). He is particularly interested in the development of new prognostic and predictive tools to improve the clinical management of arthritis patients.
He employs novel mass spectrometry based methods to robustly identify and quantify disease associated proteins in blood. He is also interested in the application of protein array technologies for autoantibody screening and flow cytometry in measuring B- and T-cell activation.
He has established research programmes in three key areas:
1. Mechanisms and biomarkers of resistance to biologic therapies.
2. Mechanisms and biomarkers of response to disease modifying anti-rheumatic drugs.
3. Alternate blood sampling methods to support home based monitoring of arthritis.
Ultimately, Dr Gibson will develop novel monitoring tools to help clinicians target those patients who do not respond well to current therapeutics or develop drug resistance over time. This would allow earlier more effective treatments in RA patients, thus preventing joint damage and reducing disability.
1. Introduction to Pharmacogenomics and Stratified Medicine
2. Inflammatory and Immunological Disease
3. Genomics, Proteomics and Metabolomics
4. Disease and Treatment 2
BSc Associate Course Director
Showing 1 to 10 of 52 publications
To view all publications please visit Ulster University Institutional Repository (UIR)
- Proteomic profile of cystic fibrosis sputum cells in adults chronically infected with Pseudomonas aeruginosaEuropean Respiratory JournalDate: (2017)
- Coincidence versus consequence: opportunities in multi-morbidity research and inflammation as a pervasive featureExpert Review of Precision Medicine and Drug DevelopmentDate: (2017)
- Association of baseline cytokine levels with anti-tumour necrosis factor treatment response in rheumatoid arthritisThe Journal of ImmunologyDate: (2017)
- The association of monocytes and Tregs with disease activity in rheumatoid arthritisThe Journal of ImmunologyDate: (2017)
- Design of a Multiplex Serum Proteome Assay to Monitor Biologic Drug Response in Rheumatoid Arthritis PatientsArthritis & RheumatologyDate: (2016)
- Siglec 1 and 2 as potential biomarkers in autoimmune diseaseProteomics Clinical ApplicationsDate: (2016)
- Musculoskeletal DiseasesPROTEOMICS - Clinical ApplicationsDate: (2016)
- A Clinically Based Protein Discovery Strategy to Identify Potential Biomarkers of Response to Anti-TNF-alpha Treatment of Psoriatic ArthritisProteomics Clinical ApplicationsDate: (2015)
- Psoriatic arthritis under a proteomic spotlight: application of novel technologies to advance diagnosis and managementCurrent Rheumatology ReportsDate: (2015)
- Anti-viral antibody profiling by high density protein arrays.ProteomicsDate: (2015)